Final overall survival (OS) for abemaciclib plus trastuzumab ± fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial - André, F; Nadal, J C; Denys, H (Ann Oncol, 2022)
et al.